Showing 1701-1710 of 4063 results for "".
- Thomas Walters, MD, Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019https://modernod.com/news/thomas-walters-md-presents-update-on-nicoxs-ncx-470-phase-2-clinical-study-in-podium-presentation-at-ascrs-2019/2476555/Nicox SA announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 phase 2 clinical study, Thomas Walters, MD, delivered a podium presentation at the annual ASCRS 2019 meeting in San Diego updating on the progress of the NCX 470 phase 2 clinical study in pat
- Stealth BioTherapeutics Doses First Patient in Phase 2 Study of Elamipretide for the Treatment of Dry AMDhttps://modernod.com/news/stealth-biotherapeutics-announces-dosing-of-first-patient-in-phase-2-study-of-elamipretide-for-the-treatment-of-dry-amd/2476423/Stealth BioTherapeutics announced that it has dosed the first patient in ReCLAIM-2, a phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy. “People with dry AMD can ultimately lose central vision. However, long before that
- Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 in Patients with Macular Edema Associated with RVOhttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2-clinical-trial-of-ar-1105-in-patients-with-macular-edema-associated-with-rvo/2476401/Aerie Pharmaceuticals announced the commencement of patient dosing in a phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This phase 2 study (AR1105-CS201) will be conducted at appr
- CXL Ophthalmics Announces Positive Results of Phase 2 Clinical Trial in Epi-On Cross-linking for Keratoconushttps://modernod.com/news/cxl-ophthalmics-announces-positive-results-of-phase-2-clinical-trial-in-epi-on-cross-linking-for-keratoconus/2480447/CXL Ophthalmics released topline results of its landmark phase 2 Trial in transepithelial (Epi-On) cross-linking. Results were summarized as
- UK, Four Other Countries to Fast-Track Vaccines for SARS-CoV-2 Variantshttps://modernod.com/news/uk-four-other-countries-to-fast-track-vaccines-for-sars-cov-2-variants/2478939/A group of regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland issued new rules Thursday aimed at speeding up the development of modified COVID-19 vaccines against emerging SAR-CoV-2 strains. The guidance, developed by the UK’s Medicines and Healthcare products
- Eyenovia Publishes PG21 Phase 2 Trial Results Examining IOP Lowering Effect and Patient Usabilityhttps://modernod.com/news/eyenovia-publishes-pg21-phase-2-trial-results-examining-iop-lowering-effect-and-patient-usability/2479637/Eyenovia announced that the full results of its phase 2 PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-
- SightGlass Vision Reports on 2-Year Chinese Study for DOT Spectacle Lenses for Myopiahttps://modernod.com/news/sightglass-vision-reports-on-2-year-chinese-study-for-dot-spectacle-lenses-for-myopia/2486985/Key Takeaways SightGlass Vision’s DOT spectacle lenses reduced myopia progression by more than 1D on average after 2 years in Chinese children aged 6 to 10
- Study Finds GLP-1 Drugs Linked to Lower Risk of Legal Blindness in Type 2 Diabeteshttps://modernod.com/news/study-finds-glp-1-drugs-linked-to-lower-risk-of-legal-blindness-in-type-2-diabetes/2486332/A large real-world study suggests that widely used GLP-1 receptor agonists—commonly prescribed for type 2 diabetes and weight management—may significantly reduce the risk of legal blindness in high-risk patients. The research,
- Oculis to Present Positive Phase 2 ACUITY Trial Results on Privosegtor for Acute Optic Neuritishttps://modernod.com/news/oculis-to-present-positive-phase-2-acuity-trial-results-on-privosegtor-for-acute-optic-neuritis/2484148/Oculis announced it will present phase 2 results for its investigational therapy Privosegtor (OCS-05) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress. The late-breaking abs
- Ashvattha Therapeutics Reports Positive Phase 2 Results for Potential First-in-Class Treatment for DME and Wet AMDhttps://modernod.com/news/ashvattha-therapeutics-reports-positive-phase-2-results-for-potential-first-in-class-treatment-for-dme-and-wet-amd/2484136/Ashvattha Therapeutics announced positive topline results from its phase 2 study of migaldendranib (MGB) in diabetic macular edema (DME) and wet age-related macular degeneration (AMD) at the Euretina Congress. MGB is